Retatrutide (GLP-3R) 10mg Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard / Gradual Approach (1 mL ≈ 10 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
Retatrutide is an investigational triple-receptor agonist peptide targeting GLP-1, GIP, and glucagon receptors, under development for obesity and type 2 diabetes.
- Phase 2 trials have shown remarkable weight-loss efficacy, with participants losing up to 24% of body weight at 48 weeks on higher doses.
- This protocol provides an educational framework for once-weekly subcutaneous administration with gradual titration to reduce gastrointestinal side effects.
Preparation & Storage:
- Reconstitute with 1.0 mL bacteriostatic water → ~10 mg/mL
- Dose range: 2–8 mg weekly (gradual escalation over 8–12 weeks)
- Measurement: 1 unit (U-100 syringe) = 0.01 mL ≈ 100 mcg
- Lyophilized: Freeze at −20 °C (−4 °F)
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (1 mL ≈ 10 mg/mL)
| Phase | Weekly Dose | Units (per injection) (mL) | Vials Needed |
|---|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) | 1 vial per dose |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) | 1 vial per dose |
| Weeks 9–12 | 6 mg (6000 mcg) | 60 units (0.60 mL) | 1 vial per dose |
| Weeks 13+ | 8 mg (8000 mcg) | 80 units (0.80 mL) | 1 vial per dose |
Frequency:
- All doses ≤10 mg can be drawn from one reconstituted 10 mg vial
- Volumes >1.0 mL should be split into 2 injections at separate sites for optimal absorption
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe
- Inject slowly along the vial wall; avoid foaming
- Gently swirl or roll until fully dissolved (do not shake)
- Label with preparation date
- Refrigerate at 2–8 °C, protected from light
- Use within 4 weeks
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Advanced / Aggressive Protocol (1 mL ≈ 10 mg/mL)
| Phase | Weekly Dose | Units (per injection) (mL) | Vials Needed |
|---|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) | 1 vial per dose |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) | 1 vial per dose |
| Weeks 9–12 | 8 mg (8000 mcg) | 80 units (0.80 mL) | 1 vial per dose |
| Weeks 13+ | 12 mg (12000 mcg) | 120 units (1.20 mL) | 2 vials per dose** |
*The 12 mg dose (highest tested in Phase 2) requires combining 2 vials, drawing 1.2 mL total, and splitting into 2 subcutaneous injections. Gradual titration is critical to reduce gastrointestinal side effects.
Note: This protocol is for educational purposes only. Retatrutide is not FDA-approved and should only be used in research settings following trial protocols.
Supplies Needed
- Retatrutide vials (10 mg each)
- 12-week standard (up to 6 mg): 5 vials
- 24-week standard (up to 8 mg): 15 vials
- 12-week aggressive (up to 8 mg): 6 vials
- U-100 Insulin Syringes (1 mL)
- 1–2 syringes per week depending on dose
- 12-week: 12–24 syringes
- 24-week: 24–48 syringes
- Bacteriostatic Water (10 mL bottles)
- 1 mL per vial for reconstitution
- 12-week: 5 mL → 1 bottle
- 24-week: 15 mL → 2 bottles
- Alcohol Swabs
- 1 per vial + 1–2 per injection site
- 12-week: ~50 swabs → 1 × 100-count box
- 24-week: ~100 swabs → 1 × 100-count box
Protocol Overview
- Goal: Achieve substantial weight loss and metabolic improvements through triple-receptor activation
- Schedule: Weekly subcutaneous injections for 12–48 weeks
- Dose Range: 2–12 mg weekly with 4-week titration steps
- Reconstitution: 1 mL per 10 mg vial (~10 mg/mL)
- Storage: Frozen lyophilized at −20 °C; reconstituted refrigerated for 4 weeks
Dosing Protocol
- Start: 2 mg weekly for 4 weeks
- Escalation: Increase by 2–4 mg every 4 weeks as tolerated
- Target Dose:
- Standard: 6–8 mg weekly
- Advanced: 12 mg weekly
- Frequency: Same day each week
- Cycle Length: Minimum 24 weeks; trials extended to 48 weeks
- Timing: Consistent day/time; rotate injection sites
Storage Instructions
Proper storage is essential to maintain peptide stability and integrity.
- Lyophilized (Unmixed): Store in a freezer at approximately −20°C (−4°F) for long-term preservation. If freezing is not available, refrigeration (2–8°C) is acceptable for shorter durations. Keep in a dry, dark environment away from moisture.
- After Reconstitution: Store the solution in a refrigerator at 2–8°C (35.6–46.4°F) at all times. Do not freeze once mixed.
- Shelf Life: Use within 28 days after reconstitution for optimal stability and reliability. Discard any remaining solution after this period.
Important Notes
Key considerations for consistency, handling, and research accuracy.
- Always use a new, sterile insulin syringe for each administration; do not reuse needles
- Follow proper aseptic technique: clean both the vial stopper and injection site with separate alcohol swabs and allow to dry fully
- Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation and avoid tissue buildup
- Administer injections slowly and steadily, allowing a few seconds before withdrawing the needle
- Keep a record of dosing, timing, and injection sites to maintain consistency throughout the protocol
- Do not use the solution if it appears cloudy, discolored, or contains visible particles
- Store and handle peptides according to recommended conditions to preserve stability
How This Works
Retatrutide activates GLP-1, GIP, and glucagon receptors:
- GLP-1 & GIP: Enhance glucose-dependent insulin secretion, suppress appetite
- Glucagon: Increases metabolic rate, promotes energy expenditure, and enhances fat burning
- Extended Half-Life (~6 days): Supports once-weekly dosing
- Overall Effect: Reduced calorie intake, increased satiety, enhanced lipid oxidation, and improved glycemic control
Potential Benefits & Considerations
Benefits
- Weight Loss: 22–24% body weight reduction at 48 weeks (8–12 mg doses)
- Glycemic Control: HbA1c reduction of 1.3–2.0% in T2DM patients; ~82% reached HbA1c ≤6.5%
- Cardiometabolic: Lower BP, LDL cholesterol, waist circumference, liver fat; >80% hepatic steatosis resolution
- Universal Response: 100% achieved ≥5% weight loss on high doses
Side Effects
- Mild-to-moderate GI symptoms: nausea, vomiting, diarrhea during dose escalation
- Dose-dependent and transient
- No severe hypoglycemia or serious treatment-related adverse events
- Safety profile comparable to GLP-1 agonists when properly titrated
Lifestyle Factors
- Follow a balanced diet to support metabolic and endocrine pathways
- Maintain proper hydration for optimal physiological function
- Prioritize sleep and recovery to support hormonal balance
- Engage in regular physical activity to complement metabolic research models
- Manage stress levels, as stress can impact hormone signaling
- Avoid excessive processed foods when focusing on metabolic studies
Injection Technique
General guidance for subcutaneous administration:
- Clean the vial stopper and injection area with alcohol and allow to dry
- Gently pinch the skin and insert the needle at a 45–90° angle
- Inject slowly and steadily without aspirating
- Hold the needle in place for a few seconds before removing
- Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-3R (10mg-20mg) remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
The Lancet (2023)
— Rosenstock J, et al. Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss)
New England Journal of Medicine (2023)
— Jastreboff AM, et al. Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss)
American Diabetes Association (2023)
— ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data)
ADA Meeting News (2023)
— Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage)
ClinicalTrials.gov
— Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760; protocol details, dosing regimens)